NCT04094610 2025-11-19A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsTurning Point Therapeutics, Inc.Phase 1/2 Recruiting75 enrolled
NCT03753685 2025-07-23X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain MetastasesFudan UniversityPhase 2 Active not recruiting27 enrolled